HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy

BACKGROUND: Adjuvant therapy comprising the HER2 receptor antagonist trastuzumab is associated with a significant improvement in disease-free and overall survival as compared to chemotherapy alone in localized HER2-positive breast cancer (BC). However, a subset of HER2-positive tumors seems to respo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Stocker, Albina, Hilbers, Marie-Luise, Gauthier, Claire, Grogg, Josias, Kullak-Ublick, Gerd A., Seifert, Burkhardt, Varga, Zsuzsanna, Trojan, Andreas
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2016
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963084/
https://ncbi.nlm.nih.gov/pubmed/27463363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0159176
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items